CMS Releases 2018 Clinical Laboratory Fee Schedule
November 20 2017 - 8:00AM
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company
focused on the discovery, development and commercialization of
clinically differentiated, high-value diagnostic solutions for
transplant patients, today announces that CMS released the 2018
Clinical Laboratory Fee Schedule confirming that the AlloMap
reimbursement rate will be increased to $3,240.
The Center for Medicare and Medicaid Services (CMS) released the
final 2018 Clinical Laboratory Fee Schedule (CLFS) today,
re-affirming the preliminary rate for AlloMap of $3,240, an
increase of 14% compared with the 2017 CMS CLFS rate of $2,840.75.
The higher 2018 reimbursement rate for AlloMap was due in part to
effective claims management, which increased the weighted median of
commercial reimbursement. This data was shared with CMS as required
by regulations associated with the Protecting Access to Medicare
Act of 2014 (PAMA). The effective date of the increase is
January 1, 2018.
“The implementation of PAMA by CMS provides a refreshing
predictability to the reimbursement of diagnostic tests,” said
Sasha King, Chief Commercial Officer at CareDx. “The updated rate
highlights the value AlloMap brings to heart transplant
patients.”
About CareDx CareDx,
Inc., headquartered in Brisbane, California, is a molecular
diagnostics company focused on the discovery, development and
commercialization of clinically differentiated, high-value
diagnostic solutions for transplant recipients. CareDx offers
products across the transplant testing continuum, including
AlloMap® and AlloSure™ for post-transplant surveillance and Olerup
SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA
testing.
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release contains forward-looking statements about our
business, research, development and commercialization efforts.
These forward-looking statements are based upon information that is
currently available to us and our current expectations, speak only
as of the date hereof, and are subject to numerous risks and
uncertainties, including risks associated with successful research,
development and planned commercialization of our technologies, that
are described in our filings with the SEC, including the Annual
Report on Form 10-K for the fiscal year ended December 31, 2016
filed by us with the SEC on April 21, 2017 and the periodic reports
that we have subsequently filed with the SEC. Any of these
may cause our actual results, performance or achievements to differ
materially and adversely from those anticipated or implied by our
forward-looking statements. We expressly disclaim any obligation,
except as required by law, or undertaking to update or revise any
such forward-looking statements.
CONTACTS:
CareDx, Inc.Sasha KingChief Commercial
Officer415-287-2393sking@caredx.com
Investor RelationsDavid ClairIntegrated Corporate Relations,
Inc.646-277-1266david.clair@icrinc.com
CareDx (NASDAQ:CDNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
CareDx (NASDAQ:CDNA)
Historical Stock Chart
From Apr 2023 to Apr 2024